Academic Journal
The effective duration of systemic therapy and the neutrophil-to-lymphocyte ratio predict the surgical advantage of primary tumor resection in patients with de novo stage IV breast cancer: a retrospective study
| Title: | The effective duration of systemic therapy and the neutrophil-to-lymphocyte ratio predict the surgical advantage of primary tumor resection in patients with de novo stage IV breast cancer: a retrospective study |
|---|---|
| Authors: | Rie Sugihara, Hidetaka Watanabe, Shuntaro Matsushima, Yuriko Katagiri, Shuko Saku, Mina Okabe, Yuko Takao, Nobutaka Iwakuma, Etsuyo Ogo, Fumihiko Fujita, Uhi Toh |
| Source: | World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-13 (2024) |
| Publisher Information: | BMC, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Surgery LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Breast cancer, Metastatic cancer, Primary tumor resection, Neutrophil-to-lymphocyte ratio, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Abstract Background The primary tumor resection (PTR) of de novo stage IV breast cancer (DnIV BC) is controversial, and previous studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) could be a poor-prognosis factor for BC. We investigated PTR’s surgical advantage related to clinical outcomes, the surgery timing in responders to systemic therapy, and whether the NLR can predict the benefit of surgery for DnIV BC. Patients and methods We retrospectively analyzed the cases of the DnIV BC patients who received systemic therapies and/or underwent PTR at our institution between January 2004 and December 2022. Blood tests and NLR measurement were performed before and after each systematic therapy and/or surgery. Results Sixty patients had undergone PTR local surgery (Surgery group); 81 patients had not undergone surgical treatment (Non-surgery group). In both groups, systemic treatment was performed as chemotherapy (95%) and/or endocrine therapy (92.5%) (p 8.1-months showed significantly longer OS (p = 0.044). The PFS and OS were significantly associated with the use of postoperative systemic therapy (p = 0.0012) and the NLR (p = 0.018). A low NLR (≤ 3) was associated with significantly better prognoses (PFS and OS; p 8.1 months) and a low pre-surgery NLR (≤ 3.0) could predict PTR’s surgical advantage for DnIV BC. These variables may help guide decisions regarding the timing of surgery for DnIV BC. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1477-7819 |
| Relation: | https://doaj.org/toc/1477-7819 |
| DOI: | 10.1186/s12957-024-03586-0 |
| Access URL: | https://doaj.org/article/da888d77f3f348358e3bf2fc77371236 |
| Accession Number: | edsdoj.888d77f3f348358e3bf2fc77371236 |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 14777819 |
|---|---|
| DOI: | 10.1186/s12957-024-03586-0 |
| Published in: | World Journal of Surgical Oncology |
| Language: | English |